## 8.5 Pharmacokinetics

In patients with chronic renal insufficiency, the mean terminal half-life of anti-Factor Xa activity
following a single intravenous dose of 5,000 IU dalteparin was 5.7 ± 2.0 hours, which is consid
‐
erably longer than in healthy volunteers, suggesting greater accumulation can be expected.